20-F/A: Clearmind Medicine Files Amendment to 20-F Annual Report Addressing Accounting Adjustments

Clearmind Medicine Inc. files an amendment to its annual report to revise the report of the predecessor Independent Public Accounting Firm and re-issue the report of the Independent Registered Public Accounting Firm regarding retrospective adjustments to financial information.

Summary

• Clearmind Medicine Inc. filed Amendment No. 1 to its Annual Report on Form 20-F for the year ended October 31, 2023.
• The amendment addresses revisions to the report of the predecessor Independent Public Accounting Firm.
• It also includes the re-issuance of the report of the Independent Registered Public Accounting Firm regarding retrospective adjustments to comparison financial information for the year ended October 31, 2021.
• These adjustments relate to the November 28, 2023 reverse share split and the change in presentation currency from Canadian dollars to U.S. dollars.
• The amendment includes amended reports from Brightman Almagor Zohar & Co. and Saturna Group Chartered Professional Accountants LLP.
• As of October 31, 2023, the company's cash and cash equivalents totaled $5,427,739.
• The company's net loss for the year ended October 31, 2023, was $8,620,837, or $42.58 per share.
• The company completed several public offerings during the year, raising gross proceeds of $7.5 million in November 2022, $3.5 million in April 2023, and $2.25 million in September 2023.
• The company's accumulated deficit as of October 31, 2023, was $18,768,063.
• The company's functional and presentation currency was changed from Canadian dollars to U.S. dollars effective November 1, 2022.
• The company's auditor, Brightman Almagor Zohar & Co., included a going concern note, indicating substantial doubt about the company's ability to continue as a going concern.
• The company's total assets as of October 31, 2023, were $5,953,288, and total liabilities were $4,969,816.
• The company's share capital and share premium as of October 31, 2023, was $17,131,223.
• The company's research and development expenses, net, for the year ended October 31, 2023, were $1,544,229.
• The company's general and administrative expenses for the year ended October 31, 2023, were $4,759,205.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant net loss, accumulated deficit, and the auditor's going concern note. While the company has raised capital, its long-term financial viability is uncertain.

Positives

• The company successfully raised capital through multiple public offerings, providing funding for operations and research.
• The company has a significant amount of cash and cash equivalents on hand, totaling $5,427,739 as of October 31, 2023.
• The company is actively engaged in research and development, as evidenced by its R&D expenses of $1,544,229 for the year ended October 31, 2023.

Negatives

• The company has a significant accumulated deficit of $18,768,063 as of October 31, 2023.
• The company experienced a net loss of $8,620,837 for the year ended October 31, 2023.
• The company's auditor included a going concern note, indicating substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain, as highlighted by the auditor's note.
• The company's continued operations are dependent on its ability to generate future cash flows or obtain additional financing.
• The ongoing war in Israel could impact the company's clinical trials and research and development activities.
• The company is exposed to foreign currency risk due to its operations in Israel and Canada.

Future Outlook

The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity.

Industry Context

Clearmind Medicine Inc. operates in the emerging psychedelic medicine industry, which is focused on developing novel treatments for mental health disorders and other health problems. The industry is characterized by significant research and development efforts, clinical trials, and regulatory hurdles. Companies in this sector often rely on external financing to fund their operations.

Comparison to Industry Standards

• It is difficult to compare Clearmind's financial results directly to industry standards due to the early stage of the psychedelic medicine industry and the variability in business models.
• Many companies in this sector are pre-revenue and heavily reliant on research and development, making traditional financial metrics less relevant.
• Comparable companies might include other publicly traded psychedelic medicine companies such as Atai Life Sciences, Compass Pathways, or Mind Medicine (MindMed) Inc., but their specific financial situations and development stages would need to be considered for a meaningful comparison.
• The success of these companies depends heavily on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain.

Related Party Transactions

• The company has a cooperation agreement with SciSparc Ltd., and certain of the company's officers and directors are also involved with SciSparc.
• The company shares office space with SciSparc and participates in paying office expenses.
• The company had related party transactions with Medigus Ltd. related to a share purchase agreement.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees' job security is uncertain due to the company's going concern risk.
• Customers may be impacted if the company is unable to continue developing and commercializing its products.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company needs to generate future cash flows or obtain additional financing to continue operations.
• The company needs to successfully navigate clinical trials and regulatory approvals for its psychedelic medicine products.
• The company needs to address the concerns raised by the auditor regarding its ability to continue as a going concern.

Key Dates

Keywords

financial statements, reverse share split, public offering, going concern, pharmaceutical, clinical trials, psychedelic medicine, research and development, accounting adjustments, financial reporting, CMND, Clearmind Medicine